Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19.
Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19.
复制标题
血清1-磷酸血清水平降低：COVID-19中临床严重程度的新预测指标。
DOI：
10.15252/emmm.202013424
复制
发表时间：
2021-01-11
影响因子：
11.1
通讯作者：
Riboni L
中科院分区：
文献类型：
--
作者：
Marfia G;Navone S;Guarnaccia L;Campanella R;Mondoni M;Locatelli M;Barassi A;Fontana L;Palumbo F;Garzia E;Ciniglio Appiani G;Chiumello D;Miozzo M;Centanni S;Riboni L
2019 年冠状病毒病 (COVID-19) 的严重程度是患者治疗和结果中的一个关键问题。本研究的目的是评估 COVID-19 患者中 1-磷酸鞘氨醇 (S1P) 的循环水平以及严重程度标志物。包括 111 名 COVID-19 患者和 47 名健康受试者。研究发现，COVID-19 的严重程度与贫血、淋巴细胞减少以及中性粒细胞与淋巴细胞比率、铁蛋白、纤维蛋白原、转氨酶、乳酸脱氢酶 (LDH)、C 反应蛋白 (CRP) 和 D-二聚体的显着增加显着相关。血清 S1P 水平与 COVID-19 严重程度呈负相关，与 CRP、LDH、铁蛋白和 D-二聚体显着相关。 S1P 的减少与红细胞数量（血浆 S1P 的主要来源）以及载脂蛋白 M 和白蛋白（血液 S1P 的主要转运蛋白）密切相关。最后，S1P 被发现是入住重症监护病房和患者预后的相关预测因素。循环 S1P 成为 COVID-19 患者严重程度/死亡率的阴性生物标志物。将异常 S1P 水平恢复到正常范围可能成为 COVID-19 患者的治疗目标。研究表明，COVID-19 患者的血清 1-磷酸鞘氨醇 (S1P) 显着降低。 S1P 的减少与红细胞数量（循环 S1P 的主要来源）以及高密度脂蛋白（HDL）/载脂蛋白 M（apoM）和白蛋白（循环 S1P 最重要的转运蛋白）的水平有关。
The severity of coronavirus disease 2019 (COVID‐19) is a crucial problem in patient treatment and outcome. The aim of this study is to evaluate circulating level of sphingosine‐1‐phosphate (S1P) along with severity markers, in COVID‐19 patients. One hundred eleven COVID‐19 patients and forty‐seven healthy subjects were included. The severity of COVID‐19 was found significantly associated with anemia, lymphocytopenia, and significant increase of neutrophil‐to‐lymphocyte ratio, ferritin, fibrinogen, aminotransferases, lactate dehydrogenase (LDH), C‐reactive protein (CRP), and D‐dimer. Serum S1P level was inversely associated with COVID‐19 severity, being significantly correlated with CRP, LDH, ferritin, and D‐dimer. The decrease in S1P was strongly associated with the number of erythrocytes, the major source of plasma S1P, and both apolipoprotein M and albumin, the major transporters of blood S1P. Not last, S1P was found to be a relevant predictor of admission to an intensive care unit, and patient’s outcome. Circulating S1P emerged as negative biomarker of severity/mortality of COVID‐19 patients. Restoring abnormal S1P levels to a normal range may have the potential to be a therapeutic target in patients with COVID‐19. The study demonstrates that patients with COVID‐19 experience a significant reduction of serum sphingosine‐1‐phosphate (S1P). The decrease of S1P associates with the number of erythrocytes, a major source of circulating S1P, as well as with the levels of high‐density lipoprotein (HDL)/apolipoprotein M (apoM) and albumin, the most important transporters of circulating S1P.
登录
查看更多内容
影响因子：
--
作者：
Oldstone MB;Rosen H
通讯作者：
Rosen H
影响因子：
4.8
作者：
Haenel, Petra;Andreani, Paul;Graeler, Markus H.
通讯作者：
Graeler, Markus H.
影响因子：
4.6
作者：
Christensen PM;Bosteen MH;Hajny S;Nielsen LB;Christoffersen C
通讯作者：
Christoffersen C
影响因子：
2.2
作者：
Ohkawa, Ryunosuke;Nakamura, Kazuhiro;Yatomi, Yutaka
通讯作者：
Yatomi, Yutaka
血清 - 神经1-磷酸盐浓度与人类的动脉粥样硬化疾病成反比。
影响因子：
3.7
作者：
Soltau I;Mudersbach E;Geissen M;Schwedhelm E;Winkler MS;Geffken M;Peine S;Schoen G;Debus ES;Larena-Avellaneda A;Daum G
通讯作者：
Daum G